84
Trials as lead sponsor
Most active programmes
The drugs appearing most often across Alnylam Pharmaceuticals's recently active trials. Comparator arms are excluded.
- Sterile Normal Saline (0.9% NaCl)15 trials
- Patisiran7 trials
- Lumasiran7 trials
- Zilebesiran5 trials
- Vutrisiran4 trials
- Givosiran4 trials
Upcoming readouts
Next primary completion dates among Alnylam Pharmaceuticals's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.
- May 2027A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes MellitusPhase 2
- Aug 2027cAPPricorn-1: A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid AngiopathyPhase 2
- Dec 2027TRITON-PN: TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary…Phase 3
- Apr 2028A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreate…Phase 2
- May 2030TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardio…Phase 3
- Sept 2030ZENITH: Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established …Phase 3
Top therapeutic areas
Conditions studied most often across Alnylam Pharmaceuticals's recently active trials.
- TTR-mediated Amyloidosis8 trials
- Hypertension6 trials
- Acute Hepatic Porphyria5 trials
- Amyloidosis, Hereditary4 trials
- Primary Hyperoxaluria4 trials
- Type 2 Diabetes Mellitus (T2DM)3 trials
Alnylam Pharmaceuticals trials
The 50 most significant of Alnylam Pharmaceuticals's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.
| Trial | Phase | Stability | Status | Enrollment | Est. readout |
|---|---|---|---|---|---|
| A Study to Evaluate ALN-4285 in Adult Healthy VolunteersNCT07295717ALN-4285 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 76 est. | 29 Dec 2026 |
| ELEVATEELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)NCT04883905 | — | Not yet scored | OngoingRecruiting | 150 est. | 1 Apr 2027 |
| A Study to Evaluate ALN-2232 in Participants With ObesityNCT07463846ALN-2232 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 156 est. | 27 Apr 2027 |
| A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes MellitusNCT07465224ALN-4324 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 40 est. | 28 May 2027 |
| HMBeaconHMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMBNCT07575308ALN-6400 | Phase 2 | Locked · track to reveal | OngoingNot yet recruiting | 24 est. | 30 Jun 2027 |
| A Study to Evaluate ALN-4915 in Adult Healthy VolunteersNCT07535606ALN-4915 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 44 est. | 31 Jul 2027 |
| cAPPricorn-1A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid AngiopathyNCT06393712ALN-APP | Phase 2 | Locked · track to reveal | OngoingRecruiting | 200 est. | 9 Aug 2027 |
| A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DMNCT06845202ALN-4324 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 144 est. | 31 Aug 2027 |
| A Study to Evaluate ALN-BCAT in Patients With Hepatocellular CarcinomaNCT06600321ALN-BCAT | Phase 1 | Locked · track to reveal | OngoingRecruiting | 158 est. | 30 Sept 2027 |
| Observational Study of Neurofilament Light Chain (NfL) as a Biomarker in Asymptomatic Carriers of the Transthyretin (TTR) Variants and Patients With Hereditary Transthyretin-mediated (hATTR) Amyloidosis With PolyneuropathyNCT06360289 | — | Not yet scored | OngoingActive, not recruiting | 346 est. | 1 Dec 2027 |
| A Study to Evaluate ALN-6222 in Participants With ObesityNCT07624071ALN-6222 | Phase 1 | Not yet scored | OngoingRecruiting | 88 est. | 14 Dec 2027 |
| TRITON-PNTRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With PolyneuropathyNCT07223203Nucresiran | Phase 3 | Locked · track to reveal | OngoingRecruiting | 125 est. | 27 Dec 2027 |
| InsigHHTA Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)NCT06659640ALN-6400 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 89 est. | 5 Jan 2028 |
| A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With CardiomyopathyNCT06679946Vutrisiran | Phase 3 | Locked · track to reveal | OngoingEnrolling by invitation | 700 est. | 31 Mar 2028 |
| A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With ZilebesiranNCT07553442ALN-AGT01 RVR | Phase 2 | Locked · track to reveal | OngoingRecruiting | 93 est. | 1 Apr 2028 |
| A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's DiseaseNCT06585449ALN-HTT02 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 66 est. | 5 Jul 2028 |
| BONAPH1DEBONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)NCT04982393 | — | Not yet scored | OngoingActive, not recruiting | 207 est. | 1 Sept 2028 |
| A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOADNCT05231785ALN-APP | Phase 1 | Locked · track to reveal | OngoingRecruiting | 60 est. | 20 Apr 2029 |
| A Study to Evaluate ALN-5288 in Patients With Alzheimer's DiseaseNCT07214727ALN-5288 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 50 est. | 6 Mar 2030 |
| A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)NCT07636811Mivelsiran | Phase 2 | Not yet scored | OngoingNot yet recruiting | 58 est. | 18 May 2030 |
| TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With CardiomyopathyNCT07052903Nucresiran | Phase 3 | Locked · track to reveal | OngoingRecruiting | 1,250 est. | 28 May 2030 |
| ZENITHZilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular DiseaseNCT07181109Zilebesiran | Phase 3 | Locked · track to reveal | OngoingRecruiting | 11,000 est. | 30 Sept 2030 |
| Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance ProgramNCT05040373 | — | Not yet scored | OngoingRecruiting | 10 est. | 12 Oct 2030 |
| DemonsTTRateDemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World SettingNCT07358078 | — | Locked · track to reveal | OngoingRecruiting | 2,000 est. | 23 Oct 2030 |
| ConTTRibuteConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)NCT04561518 | — | Locked · track to reveal | OngoingRecruiting | 1,500 est. | 31 Dec 2033 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALN-TTRSC04 in Healthy SubjectsNCT05661916ALN-TTRSC04 | Phase 1 | Locked · track to reveal | Completed | 96 est. | 30 Sept 2025 |
| A Study to Evaluate ALN-AGT01 RVR in Adult Healthy VolunteersNCT06675565ALN-AGT01 RVR | Phase 1 | Locked · track to reveal | Completed | 42 est. | 8 Sept 2025 |
| A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Moderate HypertensionNCT06423352Zilebesiran | Phase 1 | Locked · track to reveal | Completed | 36 est. | 17 Jul 2025 |
| KARDIA-3Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)NCT06272487Zilebesiran | Phase 2 | Locked · track to reveal | Completed | 375 est. | 19 Jun 2025 |
| A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DMNCT05761301ALN-KHK | Phase 1 | Locked · track to reveal | StoppedTerminated | 49 est. | 3 Apr 2025 |
| HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With CardiomyopathyNCT04153149Vutrisiran | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 655 est. | 8 May 2024 |
| KARDIA-2Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)NCT05103332Indapamide | Phase 2 | Locked · track to reveal | Completed | 663 est. | 11 Dec 2023 |
| KARDIA-1A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate HypertensionNCT04936035ALN-AGT01 | Phase 2 | Locked · track to reveal | Completed | 394 est. | 4 Apr 2023 |
| An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Participants With Primary Hyperoxaluria Type 1NCT03350451Lumasiran | Phase 2 | Locked · track to reveal | Completed | 20 est. | 7 Feb 2023 |
| A Study to Evaluate ALN-XDH in Healthy Subjects and Patients With GoutNCT05256810ALN-XDH | Phase 1 | Locked · track to reveal | StoppedTerminated | 44 est. | 25 Jan 2023 |
| A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH)NCT04565717ALN-HSD | Phase 1 | Locked · track to reveal | StoppedTerminated | 6 est. | 6 Jan 2023 |
| The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran)NCT02510261Patisiran | Phase 3 | Locked · track to reveal | Completed | 211 est. | 23 Nov 2022 |
| A Study to Evaluate Lumasiran in Adults With Recurrent Calcium Oxalate Kidney Stone Disease and Elevated Urinary Oxalate LevelsNCT05161936Lumasiran | Phase 2 | Locked · track to reveal | StoppedTerminated | 2 est. | 1 Nov 2022 |
| APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)NCT03997383Patisiran | Phase 3 | Locked · track to reveal | Completed | 360 est. | 20 Jun 2022 |
| A Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of ATTRv Amyloidosis With a V122I or T60A MutationNCT04201418Patisiran | — | Not yet scored | Completed | 67 est. | 24 May 2022 |
| A Study to Evaluate ALN-AGT01 in Patients With HypertensionNCT03934307ALN-AGT01 | Phase 1 | Locked · track to reveal | Completed | 124 est. | 20 Apr 2022 |
| A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)NCT03841448Cemdisiran | Phase 2 | Locked · track to reveal | StoppedTerminated | 31 est. | 17 Mar 2022 |
| A Study to Evaluate Long-term Safety and Clinical Activity of Givosiran (ALN-AS1) in Patient With Acute Intermittent Porphyria (AIP)NCT02949830Givosiran | Phase 1 | Locked · track to reveal | Completed | 16 est. | 5 Nov 2021 |
| ILLUMINATE-CA Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1NCT04152200Lumasiran | Phase 3 | Locked · track to reveal | Completed | 21 est. | 18 May 2021 |
| EXPLORE: A Natural History Study of Acute Hepatic Porphyria (AHP)NCT02240784 | — | Not yet scored | Completed | 136 est. | 26 Apr 2021 |
| HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)NCT03759379Patisiran | Phase 3 | Locked · track to reveal | Completed | 164 est. | 10 Nov 2020 |
| Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver TransplantNCT03862807Patisiran | Phase 3 | Locked · track to reveal | Completed | 24 est. | 6 Oct 2020 |
| ILLUMINATE-BA Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1NCT03905694Lumasiran | Phase 3 | Locked · track to reveal | Completed | 18 est. | 29 Jun 2020 |
| A Study of ALN-AAT02 in Healthy Participants and Participants With ZZ Type Alpha-1 Antitrypsin Deficiency Liver DiseaseNCT03767829ALN-AAT02 | Phase 1 | Locked · track to reveal | StoppedTerminated | 32 est. | 25 Jun 2020 |
| A Study of the Natural History of Leukocyte Chemotactic Factor 2 Amyloidosis (ALECT2) DiseaseNCT03774784 | — | Not yet scored | StoppedTerminated | 26 est. | 18 May 2020 |